Dário Silva, Sandra Cordeiro, Pedro V. Baptista, Alexandra R. Fernandes and Luis C. Branco
{"title":"甲氨蝶呤衍生盐在肺癌细胞中的合成、表征及生物活性研究。","authors":"Dário Silva, Sandra Cordeiro, Pedro V. Baptista, Alexandra R. Fernandes and Luis C. Branco","doi":"10.1039/D4MD00960F","DOIUrl":null,"url":null,"abstract":"<p >Lung cancer is one of the deadliest types of cancer, and is a public health problem worldwide. Methotrexate (MTX), a class IV drug in the biopharmaceutical classification system, is a folate antagonist that has demonstrated efficacy in cancer treatment. A suitable combination of MTX as a di-anion and biocompatible counter ions allowed the modulation of their physicochemical properties. In this work, twelve MTX salts were prepared and characterized by <small><sup>1</sup></small>H NMR, <small><sup>13</sup></small>C NMR, and elemental analysis. The antiproliferative effects of MTX salts were studied in A459 and H1975 (lung cancer cell lines) with three promising results: [C<small><sub>12</sub></small>mim]<small><sub>2</sub></small>[MTX] (IC<small><sub>50</sub></small> = 0.55 ± 0.25) > [C<small><sub>10</sub></small>-3-picoline]<small><sub>2</sub></small>[MTX] (IC<small><sub>50</sub></small> = 0.94 ± 0.03) > [C<small><sub>10</sub></small>mim]<small><sub>2</sub></small>[MTX] (IC<small><sub>50</sub></small> = 1.71 ± 0.23) in A549. These three MTX salts also demonstrated intrinsic apoptosis, avoiding necrosis and the formation of reactive oxygen species.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 8","pages":" 3593-3602"},"PeriodicalIF":3.5970,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121626/pdf/","citationCount":"0","resultStr":"{\"title\":\"Synthesis, characterization and biological activity of methotrexate-derived salts in lung cancer cells†\",\"authors\":\"Dário Silva, Sandra Cordeiro, Pedro V. Baptista, Alexandra R. Fernandes and Luis C. Branco\",\"doi\":\"10.1039/D4MD00960F\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Lung cancer is one of the deadliest types of cancer, and is a public health problem worldwide. Methotrexate (MTX), a class IV drug in the biopharmaceutical classification system, is a folate antagonist that has demonstrated efficacy in cancer treatment. A suitable combination of MTX as a di-anion and biocompatible counter ions allowed the modulation of their physicochemical properties. In this work, twelve MTX salts were prepared and characterized by <small><sup>1</sup></small>H NMR, <small><sup>13</sup></small>C NMR, and elemental analysis. The antiproliferative effects of MTX salts were studied in A459 and H1975 (lung cancer cell lines) with three promising results: [C<small><sub>12</sub></small>mim]<small><sub>2</sub></small>[MTX] (IC<small><sub>50</sub></small> = 0.55 ± 0.25) > [C<small><sub>10</sub></small>-3-picoline]<small><sub>2</sub></small>[MTX] (IC<small><sub>50</sub></small> = 0.94 ± 0.03) > [C<small><sub>10</sub></small>mim]<small><sub>2</sub></small>[MTX] (IC<small><sub>50</sub></small> = 1.71 ± 0.23) in A549. These three MTX salts also demonstrated intrinsic apoptosis, avoiding necrosis and the formation of reactive oxygen species.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 8\",\"pages\":\" 3593-3602\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121626/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00960f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00960f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Synthesis, characterization and biological activity of methotrexate-derived salts in lung cancer cells†
Lung cancer is one of the deadliest types of cancer, and is a public health problem worldwide. Methotrexate (MTX), a class IV drug in the biopharmaceutical classification system, is a folate antagonist that has demonstrated efficacy in cancer treatment. A suitable combination of MTX as a di-anion and biocompatible counter ions allowed the modulation of their physicochemical properties. In this work, twelve MTX salts were prepared and characterized by 1H NMR, 13C NMR, and elemental analysis. The antiproliferative effects of MTX salts were studied in A459 and H1975 (lung cancer cell lines) with three promising results: [C12mim]2[MTX] (IC50 = 0.55 ± 0.25) > [C10-3-picoline]2[MTX] (IC50 = 0.94 ± 0.03) > [C10mim]2[MTX] (IC50 = 1.71 ± 0.23) in A549. These three MTX salts also demonstrated intrinsic apoptosis, avoiding necrosis and the formation of reactive oxygen species.
期刊介绍：
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
